Viking Therapeutics Inc.

AI Score

0

Unlock

33.96
-4.92 (-12.65%)
At close: Jan 14, 2025, 3:59 PM
34.10
0.41%
Pre-market Jan 15, 2025, 06:52 AM EST
undefined%
Bid 33.8
Market Cap 3.78B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.94
PE Ratio (ttm) -36.13
Forward PE n/a
Analyst Buy
Ask 34.09
Volume 7,062,316
Avg. Volume (20D) 4,385,203
Open 38.46
Previous Close 38.88
Day's Range 33.35 - 38.46
52-Week Range 20.28 - 99.41
Beta undefined

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also deve...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2015
Employees 30
Stock Exchange NASDAQ
Ticker Symbol VKTX

Analyst Forecast

According to 12 analyst ratings, the average rating for VKTX stock is "Buy." The 12-month stock price forecast is $109.5, which is an increase of 222.44% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
-7.45%
Shares of pharmaceutical and healthcare stocks are... Unlock content with Pro Subscription
2 months ago · Source
-13.36%
Viking Therapeutics shares are trading lower. The company revealed weight loss results from its oral obesity drug FK2735 at ObesityWeek 2024.